Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 8, 2017
Distillery Therapeutics

Autoimmune disease; inflammation

BioCentury | May 12, 2014
Strategy

Build up to break up

Why Pfizer needs AstraZeneca to make a break-up plan work
BioCentury | Nov 5, 2012
Clinical News

Brodalumab: Phase III started

BioCentury | Apr 2, 2012
Clinical News

Brodalumab: Phase II data

BioCentury | Mar 29, 2012
Clinical News

Amgen's anti-IL-17R mAb meets psoriasis endpoint

Items per page:
1 - 6 of 6
Help Center
Username
Request a Demo
Request Training
Ask a Question